TABLE 5.
Characteristics of patients after mRNA vaccination and patients recovered from COVID-19
| Vaccination (n = 37) | Post-COVID-19 (n = 19) | p value | |
|---|---|---|---|
| Age (years) | 51 ± 13 | 53 ± 9 | .555 |
| Gender (male) | 24 (65) | 15 (79) | .364 |
| Time posttransplant (months) | 100 ± 78 | 126 ± 87 | .350 |
| Previous transplantation | 5 (14) | 1 (5) | .652 |
| Cause of end stage renal disease | .243 | ||
| Chronic glomerulonephritis | 19 (51) | 8 (42) | |
| Diabetic nephropathy | 2 (5) | 0 (0) | |
| Polycystic kidney disease | 4 (11) | 4 (21) | |
| Hypertension/nephrosclerosis | 7 (19) | 1 (5) | |
| Other | 5 (14) | 4 (21) | |
| Duration of RRT (months) | 16 ± 13 | 25 ± 26 | .446 |
| Donor type (deceased) | 35 (95) | 16 (84) | .324 |
| Body mass index (m2/kg) | 29 ± 5 | 28 ± 4 | .340 |
| Diabetes | 8 (22) | 2 (11) | .467 |
| Hypertension | 36 (97) | 19 (100) | 1.000 |
| Cardiovascular disease | 11 (30) | 4 (21) | .543 |
| Chronic pulmonary disease | 3 (8) | 1 (5) | 1.000 |
| Estimated GFRa (ml/min) | 47 ± 19 | 53 ± 15 | .222 |
| Immunosuppression at vaccination/COVID−19 | |||
| Tacrolimus | 33 (89) | 16 (84) | .679 |
| Cyclosporine | 4 (11) | 3 (16) | .679 |
| Mycophenolate mofetil/sodium | 37 (100) | 19 (100) | 1.000 |
| Depleting ALA within 6 months | 1 (3) | 1 (5) | 1.000 |
Note: Data are number of patients (percentage) or mean ± SD.
Abbreviations: ALA, antilymphocyte antibody; COVID-19, coronavirus disease 2019; GFR, glomerular filtration rate; RRT, renal replacement therapy.
a
According to CKD-EPI formula.